(2022). Platelet caspase‐1 and Bruton tyrosine kinase activation in patients with COVID‐19 is associated with disease severity and reversed in vitro by ibrutinib. Research and Practice in Thrombosis and Haemostasis.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Platelet Caspase‐1 and Bruton Tyrosine Kinase Activation in Patients with COVID‐19 Is Associated with Disease Severity and Reversed in Vitro by Ibrutinib."
Research and Practice in Thrombosis and Haemostasis 2022.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Platelet Caspase‐1 and Bruton Tyrosine Kinase Activation in Patients with COVID‐19 Is Associated with Disease Severity and Reversed in Vitro by Ibrutinib."
Research and Practice in Thrombosis and Haemostasis, 2022.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.